Your browser doesn't support javascript.
loading
Integration of Clinical Trial Development in Hematology-Oncology Fellowship Training.
Auberle, Christine; Wu, Ningying; Dipersio, John F; Waqar, Saiama N; Ratner, Lee.
Afiliação
  • Auberle C; C. Auberle is a chief fellow, Divisions of Oncology and Hematology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Wu N; N. Wu is a research statistician, Division of Public Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Dipersio JF; J.F. Dipersio is director, Center for Gene and Cellular Immunotherapy, and professor of medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Waqar SN; S.N. Waqar is director of the hematology-oncology fellowship program and associate professor of medicine, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Ratner L; L. Ratner is associate director of education, director, Section of Molecular Oncology, and professor of medicine, molecular microbiology, and pathology, Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
Acad Med ; 2024 May 30.
Article em En | MEDLINE | ID: mdl-38814121
ABSTRACT

PROBLEM:

Several barriers to physicians becoming clinical investigators exist, including inexperience, lack of available mentors, and inconsistent instructive approaches with varying degrees of participation during training. These barriers cause fewer hematology-oncology fellows to pursue academic careers. A consensus is needed on structuring education in clinical investigation paired with active participation in development of a clinical trial guided by a mentor with the goal of increasing fellow interest in clinical research and pursuit of careers in academic medicine.

APPROACH:

The clinical trial development (CTD) program was initiated at Washington University School of Medicine in St. Louis in 2002 as a hands-on learning experience for hematology and oncology fellows in the design, implementation, and publication of clinical trials. Each fellow was required to identify a mentor and propose at least 1 prospective investigator-initiated clinical trial.

OUTCOMES:

At the time of data abstraction in July 2023, 118 fellows had participated in the CTD program and initiated protocols in a variety of areas according to their interests. Fellows were included in data abstraction if their fellowship began in 2002 through 2021; the program is ongoing, and the most recent class will graduate in 2024. Disease types were evenly distributed between solid tumor oncology (60 [51%]) or classic and malignant hematology (58 [49%]). Ninety-three fellows (79%) obtained institutional review board approval, and 60 (65%) published their results. Among graduating fellows, 67 (66%) secured an academic faculty appointment. Fellows with institutional review board-approved projects had significantly higher odds of obtaining an academic faculty appointment (odds ratio, 4.96; 95% confidence interval, 1.54, 15.98; P = .007).Next StepsNext steps will be to further evaluate the effect of the mentorship network on early career productivity of trainees that graduate and the feasibility of extending the program to another institution.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acad Med Assunto da revista: EDUCACAO Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Acad Med Assunto da revista: EDUCACAO Ano de publicação: 2024 Tipo de documento: Article